ESC Premium Access

Highlights from the New England Journal of Medicine: editors’ choice

Event: ESC CONGRESS 2019
Topic: European Society of Cardiology, Other
Session type: Symposium
Date: 1 September 2019
Time: 11:00 - 12:10


3 presentations in this session

Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.

Speaker: Professor C. Rapezzi (Ferrara, IT)

Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).

Speaker: Professor J. Mcneil (Melbourne, AU)

Transcatheter Aortic Valve Replacement in Low-Risk Patients – Represented in NEJM by the PARTNER 3 and Evolut Low Risk trials.

Speaker: Doctor M. Mack (Dallas, US)

3 speakers from this session

Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)
26 presentations
0 follower

Professor John Mcneil

Monash university, Melbourne (Australia)
2 presentations
0 follower

Doctor Michael Mack

Baylor Scott & White Health, Dallas (United States of America)
3 presentations
0 follower

This platform is supported by

logo Novo Nordisk